title: Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.
abstract: OBJECTIVE
  To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events).
  
  
  METHODS
  The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study was a multicenter, randomized, double-blind, placebo-controlled clinical trial in which asymptomatic, persistently aPL-positive individuals were randomized to receive a daily dose of 81 mg of aspirin or placebo. In a separate observational and parallel study, asymptomatic, persistently aPL-positive individuals who were taking aspirin or declined randomization were followed up prospectively.
  
  
  RESULTS
  In the APLASA study, 98 individuals were randomized to receive aspirin or placebo (mean +/- SD followup period 2.30 +/- 0.95 years), of whom 48 received aspirin and 50 received placebo. In the observational study, 74 nonrandomized individuals were followed up prospectively (mean +/- SD followup period 2.46 +/- 0.76 years); 61 received aspirin and 13 did not. In the APLASA study, the acute thrombosis incidence rates were 2.75 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated subjects (hazard ratio 1.04, 95% confidence interval 0.69-1.56) (P = 0.83). Similarly, in the observational study, the acute thrombosis incidence rates were 2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for those not treated with aspirin. All but 1 patient with thrombosis in either study had concomitant thrombosis risk factors and/or systemic autoimmune disease at the time of thrombosis.
  
  
  CONCLUSIONS
  Our results suggest that asymptomatic, persistently aPL-positive individuals do not benefit from low-dose aspirin for primary thrombosis prophylaxis, have a low overall annual incidence rate of acute thrombosis, and develop vascular events when additional thrombosis risk factors are present.
authors.affiliation: Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA. erkand@hss.edu
authors.forename: Doruk
authors.initials: D
authors.lastname: Erkan
authors.forename: Melanie J
authors.initials: MJ
authors.lastname: Harrison
authors.forename: Roger
authors.initials: R
authors.lastname: Levy
authors.forename: Margaret
authors.initials: M
authors.lastname: Peterson
authors.forename: Michelle
authors.initials: M
authors.lastname: Petri
authors.forename: Lisa
authors.initials: L
authors.lastname: Sammaritano
authors.forename: Aynur
authors.initials: A
authors.lastname: Unalp-Arida
authors.forename: Veronica
authors.initials: V
authors.lastname: Vilela
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yazici
authors.forename: Michael D
authors.initials: MD
authors.lastname: Lockshin
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use*; D004311:Double-Blind Method; D005006:Ethnicity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010919:Placebos; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010919:Placebos; D001241:Aspirin